Vascular Endothelial Growth Factor (VGEF) Inhibitors Market: 36% Market Growth to Originate from North America | Technavio – QNT Press Release

[ad_1]

NEW YORK, May 17, 2022 /PRNewswire/ — Technavio categorizes the global vascular endothelial growth factor (VEGF) inhibitors market as a part of the pharmaceutical market within the overall healthcare industry. The vascular endothelial growth factor (VEGF) inhibitors market research report provides valuable insights on the post- COVID-19 impact on the market, which will help companies evaluate their business approaches.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: Key Drivers, Trends, and Challenges

• The high target affinity and specificity of VEGF inhibitors are driving the growth of the vascular endothelial growth factor (VEGF) inhibitors market.
• The increase in popularity of combination therapies is a vascular endothelial growth factor (VEGF) inhibitors market trend that is expected to have a positive impact in the coming years.
• The preference for gene therapy is expected to be a major challenge for the vascular endothelial growth factor (VEGF) inhibitors market during the forecast period.

View market report outlook to learn more about factors influencing the market.

Vendor Insights

The report identifies the following as the dominant vendors in the market:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• AVEO Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Bristol-Myers Squibb Co.
• Clovis Oncology Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Exelixis Inc.
• F. Hoffmann La Roche Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.
• Xbrane Biopharma AB

Product Insights and News

The vascular endothelial growth factor (VEGF) inhibitors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. For instance, abbvie.com, one of the leading companies vendors under the operating segment, offers research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals.

Learn more about the vendors in the market as you download your sample copy

North America’s Contribution to the Vascular Endothelial Growth Factor (VEGF) Inhibitors Market

The sales of approved VEGF inhibitors and the increasing prevalence of several cancer indications, including RCC, melanomas, and NSCLC, are expected to facilitate the vascular endothelial growth factor (VEGF) inhibitors market growth in North America over the forecast period. 36% of the market’s growth will originate from North America during the forecast period as the US and Canada are the key markets for vascular endothelial growth factor (VEGF) inhibitors in North America. Market growth in this region will be slower than the growth of the market in the Asian and ROW regions.

Download report sample right here and know more about the market contribution in APAC

Full story available on Benzinga.com

[ad_2]

Source link